Please find attached the Q1 FY 27 Financial Results
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 04 Aug 2026, 01:46 PM IST · BSE ID: 0961635c-7ef0-4be7-8310-4027f543b24d
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported higher quarterly profits and revenue, set a dividend record date, and extended its CEO's term.
🤖 AI Summary
- Consolidated net profit for Q1 FY27 was Rs. 5634.58 Lakhs, compared to Rs. 1140.66 Lakhs in Q1 FY26.
- Revenue from operations increased to Rs. 57012.81 Lakhs for the quarter ended June 30, 2026.
- Record date for FY26 final dividend set as Saturday, September 19, 2026, subject to AGM approval.
- Mr. Sushil Suri re-appointed as Chairman & Managing Director for three years from October 20, 2026.
- Extension of timeline for hiving off Medical Devices Business to subsidiary, Morepen Medipath Limited, approved.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Net Profit for Q1 FY27
5634.58 Lakhs
393.97
Consolidated Revenue from Operations for Q1 FY27
57012.81 Lakhs
34.07
Consolidated Total Income for Q1 FY27
57531.15 Lakhs
33.90
Basic & Diluted EPS for Q1 FY27
1.03 Rs.
415.00
🏢 How This Affects the Company
The increased revenue from operations indicates growth in the pharmaceutical business segment. The planned hive-off of the Medical Devices Business into a subsidiary could streamline operations.
Consolidated Net Profit for Q1 FY27 increased significantly to Rs. 5634.58 Lakhs, demonstrating improved earnings for the period. Total income for the quarter also rose to Rs. 57531.15 Lakhs.
The extension of the timeline for hiving off the Medical Devices Business suggests ongoing strategic restructuring. The re-appointment of the Chairman & Managing Director provides continuity in leadership.
No new risks were introduced by this filing. The approvals are subject to shareholder consent at the upcoming AGM.
👥 What This Means For Shareholders
✅
Action Required
Shareholders wishing to receive the final dividend for FY26 must hold shares in their demat account by the record date of September 19, 2026, if approved at the AGM.
👤
Who Is Affected
Shareholders on record as of September 19, 2026 (if the dividend is approved at the 41st AGM) will be eligible to receive the final dividend for FY26. All shareholders will vote on the re-appointment of Mr. Sushil Suri and the Medical Devices Business hive-off.
🔍
Management Signal
The re-appointment of Mr. Sushil Suri indicates management's intent for leadership continuity. The proposed hive-off and its timeline extension signal ongoing strategic business restructuring.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
41st Annual General Meeting on September 26, 2026, for approvals.
Approval of final dividend for FY26 at the upcoming AGM.
Progress of Medical Devices Business hive-off into Morepen Medipath Limited.
LOW RISK
No significant new risks or adverse events were reported in the filing.
💡 Investor Takeaway
Morepen Laboratories reported a Q1 FY27 consolidated net profit of Rs. 5634.58 Lakhs, a substantial increase from Rs. 1140.66 Lakhs in Q1 FY26. Revenue from operations also rose to Rs. 57012.81 Lakhs. The Board set September 19, 2026, as the record date for the FY26 final dividend, subject to AGM approval.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated Net Profit for Q1 FY27 grew to Rs. 5634.58 Lakhs from Rs. 1140.66 Lakhs in Q1 FY26.
- Revenue from operations for Q1 FY27 increased to Rs. 57012.81 Lakhs from Rs. 42523.88 Lakhs in Q1 FY26.
⚠️ Concerns
- Employee Benefits Expense increased to Rs. 6244.35 Lakhs in Q1 FY27 from Rs. 5523.67 Lakhs in Q1 FY26.
- Selling and Distribution Expenses rose to Rs. 5331.43 Lakhs in Q1 FY27 from Rs. 3039.64 Lakhs in Q1 FY26.
📅 Company Track Record
Morepen Laboratories Ltd. previously informed BSE on May 15, 2026, about a Board meeting scheduled for May 22, 2026, to approve Q4 and FY26 financial results. This current filing details Q1 FY27 results and other board decisions.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Morepen Laboratories' consolidated net profit for Q1 FY27?
Morepen Laboratories' consolidated net profit for the quarter ended June 30, 2026 (Q1 FY27) was Rs. 5634.58 Lakhs.
What was Morepen Laboratories' revenue from operations in Q1 FY27?
Morepen Laboratories reported revenue from operations of Rs. 57012.81 Lakhs for the quarter ended June 30, 2026.
What is the record date for Morepen Laboratories' FY26 final dividend?
The record date for determining eligibility for the final dividend for the financial year ended March 31, 2026, is Saturday, September 19, 2026, subject to approval at the 41st AGM.
Has Morepen Laboratories re-appointed its Chairman & Managing Director?
Yes, Mr. Sushil Suri has been approved for re-appointment as Chairman & Managing Director for a period of three years, from October 20, 2026, to October 19, 2029, subject to member approval at the 41st AGM.
When is Morepen Laboratories' 41st Annual General Meeting scheduled?
The 41st Annual General Meeting of Morepen Laboratories Limited is scheduled to be held on Saturday, September 26, 2026.
Questions based on this BSE filing only. For information purposes.